|
|
YTD 2021
|
Q3 2021
|
||||
|
|
|
Actual %
|
CER4 %
|
|
Actual %
|
CER %
|
|
|
$m
|
Change
|
change
|
$m
|
Change
|
change
|
- Product Sales
|
|
25,043
|
33
|
29
|
9,741
|
49
|
47
|
- Collaboration Revenue
|
|
363
|
10
|
10
|
125
|
n/m
|
n/m
|
Total Revenue
|
|
25,406
|
32
|
28
|
9,866
|
50
|
48
|
- Less pandemic COVID-19 vaccine5
|
|
2,219
|
n/m6
|
n/m
|
1,050
|
n/m
|
n/m
|
Total Revenue ex-pandemic vaccine7
|
|
23,187
|
21
|
17
|
8,816
|
34
|
32
|
Reported8 EPS9
|
|
$0.33
|
(80)
|
(65)
|
$(1.10)
|
n/m
|
n/m
|
Core10 EPS
|
|
$3.59
|
22
|
23
|
$1.08
|
14
|
15
|
Impact of pandemic vaccine on EPS
|
|
$(0.03)
|
n/m
|
n/m
|
$0.01
|
n/m
|
n/m
|
|
|
|
YTD 2021
|
Q3 2021
|
||||
|
|
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Tagrisso
|
Oncology
|
|
3,701
|
17
|
13
|
1,247
|
8
|
7
|
Imfinzi
|
|
|
1,778
|
20
|
17
|
618
|
16
|
15
|
Lynparza
|
|
|
1,719
|
21
|
18
|
588
|
27
|
25
|
Calquence
|
|
|
843
|
n/m
|
n/m
|
354
|
n/m
|
n/m
|
Enhertu
|
|
|
147
|
n/m
|
n/m
|
57
|
n/m
|
n/m
|
Farxiga
|
CVRM
|
|
2,156
|
57
|
51
|
797
|
51
|
48
|
Brilinta
|
|
|
1,124
|
(9)
|
(11)
|
375
|
(3)
|
(4)
|
Bydureon
|
|
|
293
|
(10)
|
(11)
|
95
|
(13)
|
(13)
|
roxadustat
|
|
|
148
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
Lokelma
|
|
|
122
|
n/m
|
n/m
|
49
|
n/m
|
n/m
|
Symbicort
|
R&I
|
|
2,047
|
-
|
(3)
|
676
|
13
|
11
|
Fasenra
|
|
|
901
|
35
|
32
|
322
|
34
|
33
|
Pulmicort
|
|
|
714
|
14
|
7
|
217
|
44
|
36
|
Breztri
|
|
|
130
|
n/m
|
n/m
|
47
|
n/m
|
n/m
|
Soliris16
|
Rare
|
|
798
|
n/m
|
n/m
|
798
|
(3)
|
(2)
|
Ultomiris16
|
Disease16
|
|
297
|
n/m
|
n/m
|
297
|
31
|
31
|
Strensiq16
|
|
|
159
|
n/m
|
n/m
|
159
|
7
|
8
|
PandemicCOVID-19 vaccine
|
COVID-19
|
|
2,219
|
n/m
|
n/m
|
1,050
|
n/m
|
n/m
|
|
|
YTD 2021
|
Q3 2021
|
|||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
Emerging Markets
|
|
8,618
|
34
|
33
|
28
|
3,159
|
48
|
42
|
US
|
|
8,305
|
33
|
29
|
29
|
3,471
|
53
|
53
|
Europe
|
|
5,178
|
20
|
40
|
31
|
1,918
|
52
|
49
|
Established RoW
|
|
3,305
|
13
|
28
|
24
|
1,318
|
45
|
46
|
Total
|
|
25,406
|
100
|
32
|
28
|
9,866
|
50
|
48
|
|
Medicine
|
Indication / Trial
|
Event
|
Regulatory approvalsor otherregulatory actions
|
Forxiga
|
CKD[18]
|
Approval (EU, JP)
|
roxadustat
|
Anaemia in CKD
|
Complete response letter from the US FDA
|
|
Saphnelo
|
SLE[19]
|
Approval (US, JP)
|
|
Ultomiris
|
PNH[20]
|
Approval (paediatric) (EU)
|
|
Regulatory submissions acceptance and/or submissions
|
Tagrisso
|
EGFRm[21] NSCLC[22] (adjuvant)
|
Regulatory submission (JP)
|
Enhertu
|
HER2+[23] breast
cancer (2nd-line)
|
RTOR[24] regulatory
submission (US)
|
|
Enhertu
|
HER2+ breast cancer (2nd-line)
|
Regulatory submission (EU)
|
|
Enhertu
|
HER2+ gastric cancer (2nd-line)
|
Regulatory submission (EU)
|
|
AZD7442
|
COVID-19 prophylaxis
|
EUA[25] regulatory
submission (US)
|
|
Major Phase III data readoutsor other
significant developments
|
Imfinzi
|
Biliary tract cancer (1st-line)(TOPAZ-1)
|
Phase III primary endpoint met
|
Imfinzi +
tremelimumab
|
Liver cancer (1st-line) (HIMALAYA)
|
Phase III primary endpoint met
|
|
Lynparza
|
mCRPC[26] (1st-line)
(PROpel)
|
Phase III primary endpoint met
|
|
Enhertu
|
HER2+ breast cancer (2nd-line) (DESTINY-Breast03)
|
Phase III primary endpoint met
|
|
Enhertu
|
HER2+ breast cancer (2nd-line) (DESTINY-Breast03)
|
Breakthrough Therapy Designation (US)
|
|
Fasenra
|
EG[27]
|
Orphan Drug Designation (US)
|
|
Fasenra
|
EG +/- EGE
|
Fast Track Designation (US)
|
|
Fasenra
|
Eosinophilic gastroenteritis
|
Orphan Drug Designation (US)
|
|
tezepelumab
|
EoE[28]
|
Orphan Drug Designation (US)
|
|
PT027
|
Asthma (MANDALA, DENALI)
|
Phase III primary endpoints met
|
|
Ultomiris
|
ALS[29] (CHAMPION)
|
Phase III trial stopped for futility
|
|
ALXN1840
|
Wilson disease (FoCus)
|
Phase III primary endpoint met
|
|
AZD7442
|
COVID-19 prophylaxis (PROVENT)
|
Phase III primary endpoint met
|
|
AZD7442
|
COVID-19 treatment (TACKLE)
|
Phase III primary endpoint met
|
Timing
|
Medicine
|
Indication / Trial
|
Event
|
|
Imfinzi +
tremelimumab
|
NSCLC (1st-Line)
|
Regulatory submission
|
Q4 2021
|
Lynparza
|
BRCAm HER2-negative breast cancer (adjuvant)
|
Regulatory submission
|
Lynparza
|
mCRPC (1st-line)
|
Regulatory submission
|
|
Enhertu
|
HER2+ breast cancer(2nd-line)
|
Regulatory submission
|
|
Ultomiris
|
s.c[30] formulation
in PNHand aHUS[31]
|
Regulatory submission
|
|
Ultomiris
|
gMG[32]
|
Regulatory submission
|
|
AZD2816
|
COVID-19 (variants of concern)
|
Data readout
|
|
AZD7442
|
COVID-19 outpatient treatment (TACKLE)
|
EUA regulatory submission (US),
|
|
AZD7442
|
COVID-19 pre-exposure prophylaxis (PROVENT)
|
EUA regulatory decision (US)
CMA regulatory decision (EU)
Regulatory decision (JP)
|
|
H1 2022
|
Imfinzi
|
NSCLC (unresectable, Stage III) (PACIFIC-2)
|
Data readout
|
Imfinzi
|
NSCLC (1st-line) (PEARL)
|
Data readout
|
|
Imfinzi
|
Cervical cancer (CALLA)
|
Data readout
|
|
Imfinzi
|
Biliary tract cancer
|
Regulatory submission
|
|
Imfinzi +/-
tremelimumab
|
Liver cancer (1st-line)
|
Regulatory submission
|
|
Enhertu
|
HER2-low breast cancer (DESTINY-Breast04)
|
Data readout, regulatory submission
|
|
Calquence
|
CLL[33]
|
Regulatory submission (JP)
|
|
Koselugo
|
NF1[34]
|
Regulatory submission (JP, CN)
|
|
Forxiga
|
CKD
|
Regulatory decision (CN)
|
|
Farxiga
|
HFpEF[35]
(DELIVER)
|
Data readout, regulatory submission
|
|
Brilique
|
Stroke
|
Regulatory decision (EU, CN)
|
|
Fasenra
|
Nasal polyps
|
Regulatory decision (US)
|
|
Saphnelo
|
SLE
|
Regulatory decision (EU)
|
|
tezepelumab
|
Asthma
|
Regulatory decision (US, EU, JP)
|
|
PT027
|
Asthma
|
Regulatory submission (US)
|
|
Ultomiris
|
NMOSD[36]
|
Data readout
|
|
nirsevimab
|
RSV[37]
|
Regulatory submission
|
|
Vaxzevria
|
COVID-19
|
Regulatory submission (US)
|
H2 2022
|
Tagrisso
|
EGFRm NSCLC (adjuvant)
|
Regulatory decision (JP)
|
Imfinzi
|
LS-SCLC[38] (ADRIATIC)
|
Data readout
|
|
Imfinzi
|
NSCLC (unresectable, Stage III)
|
Regulatory submission
|
|
Imfinzi
|
NSCLC (1st-line)
|
Regulatory submission
|
|
Imfinzi
|
Cervical cancer
|
Regulatory submission
|
|
Imfinzi
|
Locoregional liver cancer (EMERALD-1)
|
Data readout, regulatory submission
|
|
Enhertu
|
HER2+ breast cancer (3rd-line) (DESTINY-Breast02)
|
Data readout, regulatory submission
|
|
Enhertu
|
HER2+ gastric cancer(2nd-line)
|
Regulatory decision (EU)
|
|
Fasenra
|
HES[39] (NATRON)
|
Data readout
|
|
Fasenra
|
EoE
(MESSINA)
|
Data readout, regulatory submission
|
|
Fasenra
|
Chronic spontaneous
urticaria (ARROYO)
|
Data readout
|
|
Fasenra
|
Atopic dermatitis
(HILLIER)
|
Data readout
|
|
ALXN1840
|
Wilson
disease
|
Regulatory submission
|
|
Ultomiris
|
NMOSD
|
Regulatory submission
|
|
danicopan (ALXN2040)
|
PNH-EVH[40]
|
Data readout
|
|
acoramidis (ALXN2060)
|
ATTR-CM[41]
|
Data readout, regulatory submission
|
|
|
YTD 2021
|
Q3 2021
|
||||||
|
|
|
% of
|
Actual %
|
CER %
|
|
% of
|
Actual %
|
CER %
|
|
|
$m
|
total
|
change
|
Change
|
$m
|
total
|
change
|
change
|
Oncology
|
|
9,744
|
38
|
19
|
16
|
3,383
|
34
|
18
|
17
|
CVRM
|
|
6,028
|
24
|
14
|
10
|
2,086
|
21
|
16
|
13
|
R&I
|
|
4,456
|
18
|
16
|
12
|
1,486
|
15
|
28
|
25
|
Rare Disease16
|
|
1,311
|
5
|
n/m
|
n/m
|
1,311
|
13
|
5
|
6
|
Other medicines
|
|
1,648
|
6
|
(13)
|
(16)
|
550
|
6
|
(27)
|
(28)
|
COVID-19
|
|
2,219
|
9
|
n/m
|
n/m
|
1,050
|
11
|
n/m
|
n/m
|
Total Revenue
|
|
25,406
|
100
|
32
|
28
|
9,866
|
100
|
50
|
48
|
- Less pandemic COVID-19 vaccine
|
|
2,219
|
9
|
n/m
|
n/m
|
1,050
|
11
|
n/m
|
n/m
|
Total Revenue ex-pandemic vaccine
|
|
23,187
|
91
|
21
|
17
|
8,816
|
89
|
34
|
32
|
|
|
YTD 2021
|
Q3 2021
|
||||||
|
|
$m
|
% of total
|
Actual % change
|
CER % change
|
$m
|
% of total
|
Actual % change
|
CER % change
|
Oncology
|
|
9,593
|
38
|
21
|
17
|
3,326
|
34
|
18
|
16
|
- Tagrisso
|
|
3,701
|
15
|
17
|
13
|
1,247
|
13
|
8
|
7
|
- Imfinzi
|
|
1,778
|
7
|
20
|
17
|
618
|
6
|
16
|
15
|
- Lynparza
|
|
1,719
|
7
|
34
|
31
|
588
|
6
|
27
|
25
|
- Calquence
|
|
843
|
3
|
n/m
|
n/m
|
354
|
4
|
n/m
|
n/m
|
- Koselugo
|
|
74
|
-
|
n/m
|
n/m
|
26
|
-
|
n/m
|
n/m
|
- Enhertu
|
|
10
|
-
|
n/m
|
n/m
|
5
|
-
|
n/m
|
n/m
|
- Orpathys
|
|
10
|
-
|
n/m
|
n/m
|
10
|
-
|
n/m
|
n/m
|
- Zoladex
|
|
716
|
3
|
7
|
1
|
250
|
3
|
9
|
5
|
- Faslodex
|
|
329
|
1
|
(27)
|
(29)
|
103
|
1
|
(26)
|
(27)
|
- Iressa
|
|
149
|
1
|
(26)
|
(31)
|
41
|
-
|
(23)
|
(29)
|
- Casodex
|
|
120
|
-
|
(9)
|
(15)
|
38
|
-
|
(13)
|
(18)
|
- Arimidex
|
|
106
|
-
|
(29)
|
(31)
|
33
|
-
|
(20)
|
(20)
|
- Others
|
|
38
|
-
|
-
|
(2)
|
13
|
-
|
2
|
1
|
BioPharmaceuticals: CVRM
|
|
6,017
|
24
|
15
|
10
|
2,082
|
21
|
16
|
13
|
- Farxiga
|
|
2,152
|
8
|
57
|
51
|
796
|
8
|
51
|
48
|
- Brilinta
|
|
1,124
|
4
|
(9)
|
(11)
|
375
|
4
|
(3)
|
(4)
|
- Bydureon
|
|
293
|
1
|
(10)
|
(11)
|
95
|
1
|
(13)
|
(13)
|
- Onglyza
|
|
284
|
1
|
(22)
|
(25)
|
84
|
1
|
(23)
|
(25)
|
- Byetta
|
|
45
|
-
|
(10)
|
(10)
|
13
|
-
|
(11)
|
(6)
|
- Other diabetes
|
|
43
|
-
|
24
|
20
|
14
|
-
|
24
|
26
|
- roxadustat
|
|
144
|
1
|
n/m
|
n/m
|
55
|
1
|
n/m
|
n/m
|
- Lokelma
|
|
122
|
-
|
n/m
|
n/m
|
49
|
-
|
n/m
|
n/m
|
- Crestor
|
|
837
|
3
|
(5)
|
(9)
|
298
|
3
|
(1)
|
(4)
|
- Seloken/Toprol-XL
|
|
749
|
3
|
21
|
14
|
234
|
2
|
4
|
(2)
|
- Atacand
|
|
76
|
-
|
(58)
|
(58)
|
19
|
-
|
(65)
|
(65)
|
- Others
|
|
148
|
1
|
2
|
(3)
|
50
|
1
|
29
|
23
|
BioPharmaceuticals: R&I
|
|
4,444
|
17
|
16
|
12
|
1,483
|
15
|
28
|
25
|
- Symbicort
|
|
2,047
|
8
|
-
|
(3)
|
676
|
7
|
13
|
11
|
- Fasenra
|
|
901
|
4
|
35
|
32
|
322
|
3
|
34
|
33
|
- Pulmicort
|
|
714
|
3
|
14
|
7
|
217
|
2
|
44
|
36
|
- Daliresp
|
|
168
|
1
|
3
|
3
|
54
|
1
|
(5)
|
(6)
|
- Breztri
|
|
130
|
1
|
n/m
|
n/m
|
47
|
-
|
n/m
|
n/m
|
- Bevespi
|
|
39
|
-
|
8
|
7
|
13
|
-
|
(9)
|
(10)
|
- Saphnelo
|
|
1
|
-
|
n/m
|
n/m
|
1
|
-
|
n/m
|
n/m
|
- Others
|
|
444
|
2
|
62
|
53
|
153
|
2
|
70
|
64
|
Rare Disease16
|
|
1,311
|
5
|
n/m
|
n/m
|
1,311
|
13
|
5
|
6
|
- Soliris16
|
|
798
|
3
|
n/m
|
n/m
|
798
|
8
|
(3)
|
(2)
|
- Ultomiris16
|
|
297
|
1
|
n/m
|
n/m
|
297
|
3
|
31
|
31
|
- Strensiq16
|
|
159
|
1
|
n/m
|
n/m
|
159
|
2
|
7
|
8
|
- Andexxa16
|
|
29
|
-
|
n/m
|
n/m
|
29
|
-
|
(6)
|
(5)
|
- Kanuma16
|
|
28
|
-
|
n/m
|
n/m
|
28
|
-
|
26
|
26
|
Other medicines
|
|
1,542
|
6
|
(17)
|
(19)
|
539
|
5
|
(27)
|
(27)
|
- Nexium
|
|
999
|
4
|
(10)
|
(13)
|
259
|
3
|
(35)
|
(36)
|
- Synagis
|
|
170
|
1
|
(42)
|
(41)
|
122
|
1
|
3
|
5
|
- Losec/Prilosec
|
|
138
|
1
|
(4)
|
(10)
|
38
|
-
|
(16)
|
(21)
|
- FluMist
|
|
75
|
-
|
(35)
|
(37)
|
72
|
1
|
(37)
|
(39)
|
- Seroquel
XR/IR
|
|
74
|
-
|
(25)
|
(24)
|
24
|
-
|
(32)
|
(30)
|
- Others
|
|
86
|
-
|
(2)
|
(6)
|
24
|
-
|
23
|
20
|
COVID-19
|
|
2,136
|
8
|
n/m
|
n/m
|
1,000
|
10
|
n/m
|
n/m
|
Pandemic COVID-19 vaccine
|
|
2,136
|
8
|
n/m
|
n/m
|
1,000
|
10
|
n/m
|
n/m
|
Product Sales
|
|
25,043
|
99
|
33
|
29
|
9,741
|
99
|
49
|
47
|
Collaboration Revenue
|
|
363
|
1
|
10
|
10
|
125
|
1
|
n/m
|
n/m
|
Total Revenue
|
|
25,406
|
100
|
32
|
28
|
9,866
|
100
|
50
|
48
|
Total Revenue ex-pandemic vaccine
|
|
23,187
|
91
|
21
|
17
|
8,816
|
89
|
34
|
32
|
|
|
YTD 2021
|
Q3 2021
|
||||||
|
|
$m
|
% of total
|
Actual % change
|
CER % change
|
$m
|
% of total
|
Actual % change
|
CER % change
|
Enhertu: share of gross
profits
|
|
134
|
37
|
n/m
|
n/m
|
51
|
41
|
95
|
95
|
roxadustat: share of gross profits
|
|
4
|
1
|
(78)
|
(80)
|
1
|
1
|
(83)
|
(84)
|
Other Collaboration Revenue
|
|
225
|
62
|
(9)
|
(10)
|
73
|
58
|
n/m
|
n/m
|
Total
|
|
363
|
100
|
10
|
10
|
125
|
100
|
n/m
|
n/m
|
|
|
YTD 2021
|
Q3 2021
|
|
|||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
|
Emerging Markets
|
|
8,618
|
34
|
33
|
28
|
3,159
|
48
|
42
|
|
- China
|
|
4,699
|
18
|
17
|
8
|
1,490
|
10
|
2
|
|
- Ex-China
|
|
3,919
|
15
|
60
|
60
|
1,669
|
113
|
112
|
|
US
|
|
8,305
|
33
|
29
|
29
|
3,471
|
53
|
53
|
|
Europe
|
|
5,178
|
20
|
40
|
31
|
1,918
|
52
|
49
|
|
Established RoW
|
|
3,305
|
13
|
28
|
24
|
1,318
|
45
|
46
|
|
- Japan
|
|
2,360
|
9
|
24
|
24
|
946
|
41
|
46
|
|
- Canada
|
|
536
|
2
|
17
|
8
|
205
|
28
|
19
|
|
- Other Established
RoW
|
|
409
|
2
|
81
|
61
|
167
|
n/m
|
99
|
|
Total
|
|
25,406
|
100
|
32
|
28
|
9,866
|
50
|
48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD 2021
|
Q3 2021
|
|||||
|
|
|
% of
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
total
|
change
|
change
|
$m
|
change
|
change
|
Oncology
|
|
2,438
|
28
|
9
|
4
|
812
|
5
|
-
|
CVRM
|
|
2,916
|
34
|
19
|
14
|
992
|
20
|
14
|
R&I
|
|
1,305
|
15
|
24
|
17
|
420
|
44
|
35
|
Rare Disease16
|
|
65
|
1
|
n/m
|
n/m
|
65
|
(34)
|
(31)
|
Other medicines
|
|
755
|
9
|
4
|
-
|
219
|
(9)
|
(12)
|
COVID-19
|
|
1,139
|
13
|
n/m
|
n/m
|
651
|
n/m
|
n/m
|
Total
|
|
8,618
|
100
|
33
|
28
|
3,159
|
48
|
42
|
|
|
YTD 2021
|
Q3 2021
|
||||
|
|
|
Actual %
|
CER %
|
|
Actual %
|
CER %
|
|
|
$m
|
change
|
change
|
$m
|
change
|
change
|
Ex-China Emerging Markets
|
|
3,919
|
60
|
60
|
1,669
|
113
|
112
|
- Russia
|
|
308
|
30
|
36
|
127
|
n/m
|
n/m
|
- Brazil
|
|
450
|
91
|
98
|
169
|
n/m
|
n/m
|
- Ex-Brazil Latin America
|
|
665
|
n/m
|
n/m
|
341
|
n/m
|
n/m
|
- Ex-China Asia Pacific
|
|
1,634
|
82
|
77
|
709
|
n/m
|
n/m
|
- Middle East and Africa
|
|
862
|
12
|
15
|
323
|
36
|
38
|
|
|
YTD 2021
|
YTD 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Total Revenue
|
|
25,406
|
19,207
|
32
|
28
|
- Product Sales
|
|
25,043
|
18,879
|
33
|
29
|
- Collaboration Revenue
|
|
363
|
328
|
10
|
10
|
Cost of Sales
|
|
(7,812)
|
(3,774)
|
n/m
|
99
|
Gross Profit
|
|
17,594
|
15,433
|
14
|
11
|
Gross Profit Margin
|
|
68.8%
|
80.0%
|
-11
|
-11
|
Distribution Expense
|
|
(322)
|
(290)
|
11
|
5
|
% Total Revenue
|
|
1.3%
|
1.5%
|
-
|
-
|
R&D Expense
|
|
(7,152)
|
(4,272)
|
67
|
63
|
% Total Revenue
|
|
28.2%
|
22.2%
|
-6
|
-6
|
SG&A Expense
|
|
(10,117)
|
(8,084)
|
25
|
21
|
% Total Revenue
|
|
39.8%
|
42.1%
|
+2
|
+2
|
Other Operating Income & Expense
|
|
1,345
|
888
|
51
|
50
|
% Total Revenue
|
|
5.3%
|
4.6%
|
+1
|
+1
|
Operating Profit
|
|
1,348
|
3,675
|
(63)
|
(57)
|
Operating Margin
|
|
5.3%
|
19.1%
|
-14
|
-13
|
Net Finance Expense
|
|
(922)
|
(905)
|
2
|
-
|
Joint Ventures and Associates
|
|
(55)
|
(21)
|
n/m
|
n/m
|
Profit Before Tax
|
|
371
|
2,749
|
(86)
|
(77)
|
Taxation
|
|
90
|
(610)
|
n/m
|
n/m
|
Tax Rate
|
|
-24%
|
22%
|
|
|
Profit After Tax
|
|
461
|
2,139
|
(78)
|
(63)
|
Earnings per share
|
|
$0.33
|
$1.66
|
(80)
|
(65)
|
|
|
Q3 2021
|
Q3 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Total Revenue
|
|
9,866
|
6,578
|
50
|
48
|
- Product Sales
|
|
9,741
|
6,520
|
49
|
47
|
- Collaboration Revenue
|
|
125
|
58
|
n/m
|
n/m
|
Cost of Sales
|
|
(3,757)
|
(1,370)
|
n/m
|
n/m
|
Gross Profit
|
|
6,109
|
5,208
|
17
|
16
|
Gross Profit Margin
|
|
61.4%
|
79.0%
|
-18
|
-18
|
Distribution Expense
|
|
(120)
|
(99)
|
21
|
18
|
% Total Revenue
|
|
1.2%
|
1.5%
|
-
|
-
|
R&D Expense
|
|
(3,610)
|
(1,495)
|
n/m
|
n/m
|
% Total Revenue
|
|
36.6%
|
22.7%
|
-14
|
-14
|
SG&A Expense
|
|
(4,090)
|
(2,730)
|
50
|
47
|
% Total Revenue
|
|
41.5%
|
41.5%
|
-
|
-
|
Other Operating Income & Expense
|
|
37
|
287
|
(87)
|
(87)
|
% Total Revenue
|
|
0.4%
|
4.4%
|
-4
|
-4
|
Operating (Loss)/Profit
|
|
(1,674)
|
1,171
|
n/m
|
n/m
|
Operating Margin
|
|
-17.0%
|
17.8%
|
-35
|
-35
|
Net Finance Expense
|
|
(320)
|
(317)
|
1
|
(1)
|
Joint Ventures and Associates
|
|
(7)
|
(1)
|
n/m
|
n/m
|
(Loss)/Profit Before Tax
|
|
(2,001)
|
853
|
n/m
|
n/m
|
Taxation
|
|
350
|
(202)
|
n/m
|
n/m
|
Tax Rate
|
|
-18%
|
24%
|
|
|
(Loss)/Profit After Tax
|
|
(1,651)
|
651
|
n/m
|
n/m
|
(Loss)/Earnings per share
|
|
$(1.10)
|
$0.49
|
n/m
|
n/m
|
|
|
YTD 2021
|
YTD 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Reported Profit Before Tax
|
|
371
|
2,749
|
(86)
|
(77)
|
Net Finance Expense
|
|
922
|
905
|
2
|
-
|
Joint Venture and Associates
|
|
55
|
21
|
n/m
|
n/m
|
Depreciation, Amortisation and Impairment
|
|
4,338
|
2,352
|
84
|
77
|
EBITDA
|
|
5,686
|
6,027
|
(6)
|
(6)
|
|
|
Q3 2021
|
Q3 2020
|
Actual
|
CER
|
|
|
$m
|
$m
|
% change
|
% change
|
Reported (Loss)/Profit Before Tax
|
|
(2,001)
|
853
|
n/m
|
n/m
|
Net Finance Expense
|
|
320
|
317
|
1
|
(1)
|
Joint Venture and Associates
|
|
7
|
1
|
n/m
|
n/m
|
Depreciation, Amortisation and Impairment
|
|
2,788
|
801
|
n/m
|
n/m
|
EBITDA
|
|
1,114
|
1,972
|
(43)
|
(45)
|
YTD 2021
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion[55]
|
Other[56]
|
Core[57]
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
17,594
|
221
|
47
|
1,049
|
2
|
18,913
|
22
|
19
|
Gross Profit Margin
|
68.8%
|
|
|
|
|
74.1%
|
-6
|
-6
|
Distribution Expense
|
(322)
|
-
|
-
|
-
|
-
|
(322)
|
11
|
5
|
R&D Expense
|
(7,152)
|
155
|
1,395
|
10
|
1
|
(5,591)
|
34
|
30
|
SG&A Expense
|
(10,117)
|
172
|
1,977
|
166
|
66
|
(7,736)
|
19
|
14
|
Total Operating Expense
|
(17,591)
|
327
|
3,372
|
176
|
67
|
(13,649)
|
24
|
20
|
Other Operating Income & Expense
|
1,345
|
-
|
1
|
-
|
-
|
1,346
|
51
|
50
|
Operating Profit
|
1,348
|
548
|
3,420
|
1,225
|
69
|
6,610
|
21
|
23
|
Operating Margin
|
5.3%
|
|
|
|
|
26.0%
|
-2
|
-1
|
Net Finance Expense
|
(922)
|
-
|
-
|
-
|
294
|
(628)
|
9
|
10
|
Taxation
|
90
|
(93)
|
(697)
|
(242)
|
(55)
|
(997)
|
(2)
|
(1)
|
EPS
|
$0.33
|
$0.33
|
$1.99
|
$0.72
|
$0.22
|
$3.59
|
22
|
23
|
Q3 2021
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Acquisition of Alexion55
|
Other56
|
Core57
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
6,109
|
208
|
14
|
1,049
|
2
|
7,382
|
41
|
39
|
Gross Profit Margin
|
61.4%
|
|
|
|
|
74.5%
|
-5
|
-5
|
Distribution Expense
|
(120)
|
-
|
-
|
-
|
-
|
(120)
|
21
|
18
|
R&D Expense
|
(3,610)
|
123
|
1,324
|
10
|
1
|
(2,152)
|
48
|
46
|
SG&A Expense
|
(4,090)
|
97
|
1,013
|
124
|
(10)
|
(2,866)
|
32
|
29
|
Total Operating Expense
|
(7,820)
|
220
|
2,337
|
134
|
(9)
|
(5,138)
|
38
|
35
|
Other Operating Income & Expense
|
37
|
-
|
-
|
-
|
-
|
37
|
(87)
|
(87)
|
Operating (Loss)/Profit
|
(1,674)
|
428
|
2,351
|
1,183
|
(7)
|
2,281
|
27
|
28
|
Operating Margin
|
-17.0%
|
|
|
|
|
23.1%
|
-4
|
-4
|
Net Finance Expense
|
(320)
|
-
|
-
|
-
|
101
|
(219)
|
5
|
4
|
Taxation
|
350
|
(69)
|
(468)
|
(242)
|
(14)
|
(443)
|
29
|
31
|
EPS
|
$(1.10)
|
$0.24
|
$1.26
|
$0.63
|
$0.05
|
$1.08
|
14
|
15
|
|
|
YTD 2021
|
YTD 2020
|
Change
|
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
|
1,348
|
3,675
|
(2,327)
|
Depreciation, Amortisation and Impairment
|
|
4,338
|
2,352
|
1,986
|
Decrease/(increase) in Working Capital and Short-term
Provisions
|
|
2,063
|
(255)
|
2,318
|
Gains on Disposal of Intangible Assets
|
|
(371)
|
(535)
|
164
|
Gains on Disposal of Investments in Associates and Joint
Ventures
|
|
(776)
|
-
|
(776)
|
Non-Cash and Other Movements
|
|
(337)
|
(498)
|
161
|
Interest Paid
|
|
(522)
|
(517)
|
(5)
|
Taxation Paid
|
|
(1,198)
|
(1,221)
|
23
|
Net Cash Inflow from Operating Activities
|
|
4,545
|
3,001
|
1,544
|
Net Cash (Outflow)/Inflow before Financing Activities
|
|
(5,600)
|
2,578
|
(8,178)
|
Net Cash Inflow from Financing Activities
|
|
4,700
|
7
|
4,693
|
|
|
At 30 Sep 2021
|
At 31 Dec 2020
|
At 30 Sep 2020
|
|
$m
|
$m
|
$m
|
|
Cash
and cash equivalents
|
|
7,067
|
7,832
|
8,072
|
Other
investments
|
|
82
|
160
|
374
|
Cash and investments
|
|
7,149
|
7,992
|
8,446
|
Overdrafts
and short-term borrowings
|
|
(605)
|
(658)
|
(1,216)
|
Lease
liabilities
|
|
(962)
|
(681)
|
(666)
|
Current
instalments of loans
|
|
(2,139)
|
(1,536)
|
(2,186)
|
Non-current
instalments of loans
|
|
(28,206)
|
(17,505)
|
(18,271)
|
Interest-bearing loans and borrowings
(Gross Debt)
|
|
(31,912)
|
(20,380)
|
(22,339)
|
Net
derivatives
|
|
90
|
278
|
131
|
Net Debt
|
|
(24,673)
|
(12,110)
|
(13,762)
|
|
|
YTD 2021
|
FY 2020
|
YTD 2020
|
|
$m
|
$m
|
$m
|
|
Total revenue
|
|
-
|
-
|
-
|
Gross profit
|
|
-
|
-
|
-
|
Operating loss
|
|
(131)
|
(45)
|
(1)
|
Loss for the period
|
|
(553)
|
(663)
|
(463)
|
Transactions with subsidiaries that are not issuers or
guarantors
|
|
5,731
|
2,637
|
484
|
|
|
At 30 Sep 2021
|
At 31 Dec 2020
|
At 30 Sep 2020
|
|
$m
|
$m
|
$m
|
|
Current assets
|
|
12
|
26
|
1
|
Non-current assets
|
|
-
|
4
|
-
|
Current liabilities
|
|
(2,347)
|
(1,720)
|
(961)
|
Non-current liabilities
|
|
(25,721)
|
(17,161)
|
(17,913)
|
Amounts due from subsidiaries that are not issuers or
guarantors
|
|
12,137
|
7,011
|
6,484
|
Amounts due to subsidiaries that are not issuers or
guarantors
|
|
(299)
|
(290)
|
(295)
|
|
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5%
Strengthening in Exchange Rate versus USD ($m)[58]
|
||
Currency
|
Primary Relevance
|
|
FY 2020[59]
|
YTD 2021[60]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product Sales
|
|
6.90
|
6.44
|
7
|
312
|
186
|
EUR
|
Product Sales
|
|
0.88
|
0.84
|
5
|
214
|
75
|
JPY
|
Product Sales
|
|
106.74
|
108.52
|
(2)
|
154
|
102
|
Other[61]
|
|
|
|
|
|
250
|
116
|
GBP
|
Operating Expense
|
|
0.78
|
0.72
|
7
|
35
|
(81)
|
SEK
|
Operating Expense
|
|
9.20
|
8.49
|
8
|
5
|
(59)
|
New molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
28
|
Oncology
- Tagrisso - NSCLC
- Imfinzi - multiple cancers
- Lynparza - multiple cancers
- Enhertu - multiple cancers
- Calquence - blood cancers
- Orpathys - NSCLC
-
tremelimumab - multiple cancers
-
capivasertib - breast, prostate cancer
-
monalizumab - head & neck cancer
-
camizestrant - breast cancer
-
datopotamab deruxtecan - lung cancer
CVRM
- Farxiga - multiple indications
-
roxadustat - anaemia in MDS
- Lokelma - hyperkalaemia in CKD
Respiratory & Immunology
- Fasenra - multiple indications
- Breztri - asthma
-
tezepelumab - multiple indications
-
PT027 - asthma
- Saphnelo (anifrolumab) - SLE
-
brazikumab - inflammatory bowel disease
Rare Disease
- Ultomiris - multiple indications
-
ALXN1840 - Wilson disease
-
CAEL-101 - AL amyloidosis
-
acoramidis (ALXN2060) - ATTR-CM
-
danicopan (ALXN2040) - PNH with EVH
Other
-
nirsevimab - RSV
COVID-19
- Vaxzevria
-
AZD7442
|
Total projects
in clinical development
|
159
|
|
Total projects
in total pipeline
|
175
|
|
Trial (population)
|
Design
|
Timeline
|
Status
|
NeoADAURA
(neo-adjuvant EGFRm NSCLC)
|
Placebo or Tagrisso
|
FPCD[63]:
Q1 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
ADAURA
(adjuvant EGFRm NSCLC)
|
Placebo or Tagrisso
|
FPCD: Q4 2015
LPCD[64]:
Q1 2019
|
Trial unblinded early due to overwhelming efficacy
Regulatory approval(US, EU, CN)
|
LAURA
(locally advanced, unresectable EGFRm NSCLC)
|
Placebo or Tagrisso
|
FPCD: Q4 2018
First data anticipated: 2022+
|
Recruitment ongoing
|
FLAURA2
(EGFRm NSCLC, 1st-line)
|
Tagrisso or Tagrisso + platinum-based chemotherapy
doublet
|
FPCD: Q4 2019
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
AEGEAN
(neo-adjuvant NSCLC)
|
SoC[71] chemotherapy
+/- Imfinzi, followed by surgery, followed by placebo
or Imfinzi
|
FPCD: Q1 2019
First data anticipated: 2022+
|
Recruitment ongoing
|
ADJUVANT BR.31[72]
(Stage IB-IIIA resected NSCLC)
|
Placebo or Imfinzi
|
FPCD: Q1 2015
LPCD: Q1 2020
First data anticipated: 2022+
|
Recruitment completed
|
MERMAID-1
(Stage II-III
resected NSCLC)
|
SoC chemotherapy +/- Imfinzi
|
FPCD: Q3 2020
First data anticipated: 2022+
|
Recruitment ongoing
|
MERMAID-2
(Stage II-III
NSCLC with minimal residual disease)
|
Placebo or Imfinzi
|
FPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
PACIFIC-2
(Stage III unresectable locally advanced NSCLC
(concurrent CRT))
|
Placebo or
Imfinzi
|
FPCD: Q2 2018
LPCD: Q3 2019
First data anticipated:H2 2021
|
Recruitment completed
|
ADRIATIC
(LS-SCLC)
|
cCRT, followed by placebo or Imfinzi or Imfinzi + tremelimumab
|
FPCD: Q4 2018
LPCD: Q3 2021
First data anticipated:H2 2022
|
Recruitment completed
|
PEARL
(Stage IV NSCLC, 1st-line)
|
SoC chemotherapy or Imfinzi
|
FPCD: Q1 2017
LPCD: Q1 2019
First data anticipated:H1 2022
|
Recruitment completed
|
POSEIDON
(Stage IV NSCLC, 1st-line)
|
SoC chemotherapy or SoC + Imfinzi or SoC + Imfinzi + tremelimumab
|
FPCD: Q2 2017
LPCD: Q4 2018
|
PFS primary endpoint met; OS primary endpoint met
for Imfinzi + tremelimumab
|
Trial (population)
|
Design
|
Timeline
|
Status
|
POTOMAC
(non-muscle invasive bladder cancer)
|
SoC BCG[73] +/- Imfinzi
|
FPCD: Q4 2018
LPCD: Q4 2020
First data anticipated: 2022+
|
Recruitment completed
|
NIAGARA
(muscle-invasive bladder cancer)
|
Neo-adjuvant cisplatin and gemcitabine SoC chemotherapy or SoC
+ Imfinzi, followed by adjuvant placebo
or Imfinzi
|
FPCD: Q4 2018LPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment completed
|
EMERALD-1
(locoregional HCC[74])
|
TACE[75] followed
by placebo or TACE + Imfinzi, followed by Imfinzi + bevacizumab or TACE
+ Imfinzi followed by Imfinzi
|
FPCD: Q1 2019LPCD: Q3 2021
First data anticipated:H2 2022
|
Recruitment completed
|
EMERALD-2
(locoregional HCC at high risk of recurrence after surgery or
radiofrequency ablation)
|
Adjuvant Imfinzi or Imfinzi + bevacizumab
|
FPCD: Q2 2019
First data anticipated: 2022+
|
Recruitment ongoing
|
CALLA
(locally advanced cervical cancer)
|
CRT +/- Imfinzi, followed by placebo or Imfinzi
|
FPCD: Q1 2019
LPCD: Q4 2020
First data anticipated:H1 2022
|
Recruitment completed
|
MATTERHORN
(resectable gastric and gastroesophageal cancer)
|
Neoadjuvant Imfinzi + FLOT[76] chemotherapy
+/- adjuvant Imfinzi
|
FPCD: Q4 2020
First data anticipated: 2022+
|
Recruitment ongoing
|
KUNLUN
(locally advanced, unresectable oesophageal squamous cell
carcinoma)
|
Definitive CRT or CRT +/- Imfinzi
|
FPCD: Q4 2020
First data anticipated: 2022+
|
Recruitment ongoing
|
NILE(Stage IV cisplatin chemotherapy- eligible bladder cancer,
1st-line)
|
SoC chemotherapy orSoC + Imfinzi orSoC + Imfinzi + tremelimumab
|
FPCD: Q4 2018LPCD: Q2 2021
First data anticipated: 2022+
|
Recruitment completed
|
VOLGA
(Muscle invasive bladder cancer ineligible to
cisplatin)
|
SoC cystectomy or Imfinzi + tremelimumab + enfortumab vedotin
or Imfinzi + enfortumab vedotin
|
FPCD: Q4 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
HIMALAYA
(Stage IV unresectable HCC, 1st-line)
|
Sorafenib or Imfinzi or Imfinzi + tremelimumab
|
FPCD: Q4 2017
LPCD: Q4 2019
|
Primary endpoint met
Orphan Drug Designation (US)
|
TOPAZ-1
(Stage IV biliary-tract cancer, 1st-line)
|
Gemcitabine and cisplatin SoC chemotherapy or SoC
+ Imfinzi
|
FPCD: Q2 2019
LPCD: Q4 2020
|
Primary endpoint metOrphan Drug Designation (US)
|
Trial (population)
|
Design
|
Timeline
|
Status
|
OlympiA
(adjuvant BRCAm[77] breast
cancer)
|
Placebo or Lynparza
|
FPCD: Q2 2014
LPCD: Q2 2019
|
Primary endpoint met
|
MONO-OLA1
(BRCAwt[78] advanced
ovarian cancer 1L maintenance)
|
Placebo or Lynparza
|
FPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
DuO-O
(advanced ovarian cancer, 1st-line)
|
Chemotherapy + bevacizumab or chemotherapy + bevacizumab
+ Imfinzi +/- Lynparza maintenance
|
FPCD: Q1
2019
First data anticipated: 2022+
|
Recruitment ongoing
|
DuO-E
(advanced endometrial cancer, 1st-line)
|
Chemotherapy or chemotherapy + Imfinzi + Imfinzi maintenance or chemotherapy
+ Imfinzi followed by Imfinzi + Lynparza maintenance
|
FPCD: Q2
2020
First data anticipated: 2022+
|
Recruitment ongoing
|
PROpel
(Stage IV, castration-resistant prostate cancer)
|
Abiraterone orabiraterone + Lynparza
|
FPCD: Q4 2018
|
Primary endpoint met
|
Trial (population)
|
Design
|
Timeline
|
Status
|
DESTINY-Breast02-U301, Phase III
(Stage IV, HER2+ breast cancer post trastuzumab
emtansine)
|
SoC chemotherapy or Enhertu
|
FPCD: Q3 2018
LPCD: Q4 2020
First data anticipated: H2 2022
|
Recruitment completed
|
DESTINY-Breast03-U302, Phase III
(Stage IV, HER2+ breast cancer, 2nd-line)
|
Trastuzumab emtansine or Enhertu
|
FPCD: Q3 2018
LPCD: Q2 2020
|
Primary endpoint met
Breakthrough Therapy Designation (US)
|
DESTINY-Breast04, Phase III
(Stage IV, HER2-low breast cancer, 2nd-line)
|
SoC chemotherapy or Enhertu
|
FPCD: Q4 2018
LPCD: Q4 2020
First data anticipated: H1 2022
|
Recruitment completed
|
DESTINY-Breast05, Phase III
(high-risk HER2+ breast cancer, post-neoadjuvant)
|
Trastuzumab emtansine or Enhertu
|
FPCD Q4 2020First data anticipated: 2022+
|
Recruitment ongoing
|
DESTINY-Breast06, Phase III
(Stage IV, HER2-low breast cancer, post endocrine
therapy)
|
SoC chemotherapy or Enhertu
|
FPCD: Q3 2020
First data anticipated: 2022+
|
Recruitment ongoing
|
DESTINY-Breast09, Phase III
(Stage IV, HER2+ breast cancer, 1st-line)
|
SoC chemotherapy + trastuzumab + pertuzumab
or Enhertu + pertuzumab or Enhertu
|
FPCD: Q2 2021First data anticipated: 2022+
|
Recruitment ongoing
|
DESTINY-Gastric01, Phase II
(Stage IV, HER2+ gastric cancer)
|
SoC chemotherapy or Enhertu
|
FPCD: Q4 2017
LPCD: Q2 2019
|
Primary endpoint met
Breakthrough Therapy Designation (US)
Regulatory approval (US, JP)
|
DESTINY-Gastric02, Phase II
(Stage IV, HER2+ gastric cancer)
|
Enhertu
|
FPCD: Q4 2019LPCD: Q4 2020
|
Positive data readoutRecruitment completed
|
DESTINY-Gastric04, Phase III
(Stage IV, HER2+ gastric cancer, 2nd-line)
|
Paclitaxel + ramucirumab or Enhertu
|
FPCD: Q2 2021First data anticipated: 2022+
|
Recruitment ongoing
|
DESTINY-Lung04,Phase III
(Stage III, HER2 mutated NSCLC, 1st-line)
|
SoC platinum chemotherapy, pemetrexed and pembrolizumab
or Enhertu
|
Initiating
First data anticipated: 2022+
|
Initiating
|
Trial (population)
|
Design
|
Timeline
|
Status
|
ESCALADE
(Diffuse large B-cell lymphoma)
|
SoC R-CHOP[82] +/- Calquence
|
FPCD: Q2 2020
Data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
SERENA-4
(ER+, HER2-, advanced breast cancer)
|
Palbociclib + anastrazole or albociclib + camizestrant
|
FPCD: Q1 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
SERENA-6
(HR+, HER2-, metastatic breast cancer)
|
Palbociclib or abemaciclib + camizestrant, or anastrozole or
letrozole + albociclib or abemaciclib
|
FPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
TROPION-Lung01
(Stage IV NSCLC,2nd-line)
|
SoC chemotherapy or datopotamab deruxtecan
|
FPCD: Q1 2021First data anticipated: 2022+
|
Recruitment ongoing
|
TROPION-Breast01
|
SoC chemotherapy or datopotamab deruxtecan
|
InitiatingFirst data anticipated: 2022+
|
Initiating
|
Trial (population)
|
Design
|
Timeline
|
Status
|
Brilinta
|
|||
THALES
(c.11,000 patients with acute ischaemic stroke[87] or
transient ischaemic attack)
|
Aspirin plus placebo or aspirin plus Brilinta 90mg BID
|
FPCD: Q1 2018
LPCD: Q4 2019
|
Primary endpoint met
Regulatory approval (US)
|
Farxiga
|
|||
DELIVER
(c.6,300 patients with HF (HFpEF) with and without
T2D)
|
Placebo or Farxiga 10mg QD
|
FPCD: Q4 2018
LPCD: Q4 2020
First data anticipated: H1 2022
|
Recruitment completed
Fast Track[88] designation
(US)
|
DAPA-MI
(c.6,400 patients with confirmed MI, either
STEMI[89] or
NSTEMI[90],
within the preceding seven days)
|
Placebo or Farxiga 10mg QD
|
FPCD: Q4 2020
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
DIALIZE
(c.2,300 patients with recurrent hyperkalaemia on chronic
haemodialysis)
|
Placebo or Lokelma 10mg QD for 4 weeks on non-dialysis days, thereafter
adjusted monthly
|
FPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
STABILIZE-CKD
(c.1,360 patients
with CKD and hyperkalaemia or at risk of
hyperkalaemia)
|
Placebo or Lokelma 5g QOD to 15g QD plus lisonopril or
valsartan
|
FPCD: Q4 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
KALOS
(asthma)
|
Budesonide/formoterol or Breztri
|
FPCD: Q1 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
LOGOS
(asthma)
|
Budesonide/formoterol or Breztri
|
FPCD: Q1 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
OSTRO
(severe bilateral nasal polyps)
|
Placebo or Fasenra 30mg
Q8W[91] s.c.
|
FPCD: Q1 2018
LPCD: Q2 2019
|
Co-primary endpoints met
|
RESOLUTE
(moderate to very severe COPD with a history of exacerbations and
elevated peripheral blood eosinophils)
|
Placebo or Fasenra 100mg Q8W s.c.
|
FPCD: Q4 2019
First data anticipated: 2022+
|
Recruitment ongoing
|
MANDARA
(eosinophilic granulomatosis with polyangiitis)
|
Mepolizumab 3x100mg Q4W[92] or Fasenra 30mg
s.c.
|
FPCD: Q4 2019
First data anticipated: 2022+
|
Recruitment ongoing
Orphan Drug Designation (US)
|
NATRON
(HES)
|
Placebo or Fasenra 30mg Q4W s.c.
|
FPCD: Q3 2020
First data anticipated:
H2 2022
|
Recruitment ongoing
Orphan Drug Designation (US)
|
MESSINA
(EoE)
|
Placebo or Fasenra 30mg Q4W s.c.
|
FPCD: Q4 2020
First data anticipated:
H2 2022
|
Recruitment ongoing
Orphan Drug Designation (US)
|
FJORD
(bullous pemphigoid)
|
Placebo or Fasenra 30mg Q4W s.c.
|
FPCD: Q2 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
MAHALE
(non-cystic fibrosis bronchiectasis)
|
Placebo or Fasenra 30mg Q4W s.c.
|
FPCD: Q3 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
HUDSON (EG/EGE)
|
Placebo or Fasenra 30mg Q4W s.c.
|
First data anticipated: 2022+
|
Initiating
|
Trial (population)
|
Design
|
Timeline
|
Status
|
NAVIGATOR
(asthma)
|
Placebo or tezepelumab 210mg Q4W s.c.
|
FPCD: Q1 2018
LPCD: Q3 2019
|
Primary endpoint met
Breakthrough Therapy Designation (US)
|
WAYPOINT
(chronic rhinosinusitis with nasal polyps)
|
Placebo or tezepelumab 210mg Q4W s.c.
|
FPCD: Q2 2021
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial
|
Design
|
Timeline
|
Status
|
TYREE
(asthma withexercise-induced broncho constriction)
|
Placebo or PT027 160/180mcg, single dose
|
FPCD: Q1 2020
LPCD: Q3 2020
|
Primary endpoint met
|
MANDALA
(asthma)
|
Albuterol or PT027 80/180mcg or PT027 160/180mcg (all 'as
needed')
|
FPCD: Q4 2018
LPCD: Q1 2021
|
Primary endpoint met
|
DENALI
(asthma)
|
Placebo or albuterol 180mcg or budesonide 160mcg or PT027 80/180mcg
or PT027 160/180mcg QID
|
FPCD: Q2 2019
LPCD: Q2 2021
|
Dual primary endpoints met
|
Trial (population)
|
Design
|
Timeline
|
Status
|
TULIP 1
(moderate to severely active SLE)
|
Placebo or Saphnelo
150mg or 300mg i.v.[93]
Q4W[94]
|
FPCD: Q4 2015
LPCD: Q4 2017
|
Primary endpoint not met
Regulatory approval (US)
|
TULIP 2
(moderate to severely active SLE)
|
Placebo or Saphnelo 300mg i.v. Q4W
|
FPCD: Q4 2015
LPCD: Q4 2017
|
Primary endpoint met
Regulatory approval (US)
|
TULIP-SC (moderate to severely active SLE)
|
Placebo or Saphnelo
120mg s.c. Q1W[95]
|
First data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
NMOSD
|
External placebo-controlled open-label Ultomiris Q8W
|
FPCD: Q4 2019
LPCD: H1 2022
Data anticipated: 1H 2022
|
Recruitment completed
|
gMG
|
Placebo or Ultomiris Q8W
|
FPCD: Q1 2019
LPCD: Q2 2021
|
Primary endpoint met
|
CM-TMA[98]
|
Placebo or Ultomiris Q8W
|
FPCD: Q3 2021
Data anticipated: 2022+
|
Recruitment ongoing
|
HSCT-TMA[99]
Adult
|
Placebo or Ultomiris Q8W
|
FPCD: Q4 2020
Data anticipated: 2022+
|
Recruitment ongoing
|
Trial (population)
|
Design
|
Timeline
|
Status
|
MELODY
(healthy late preterm and term infants)
|
Placebo or nirsevimab IM[100]
|
FPCD: Q3 2019LPCD: Q3 2020
|
Primary endpoint met
Breakthrough therapy designation (US, EU, CN)
|
MEDLEY
(high-risk children)
|
Synagis or nirsevimab
IM
|
FPCD: Q3 2019
LPCD: Q4 2020
|
Safety objective met
|
Trial
|
Design
|
Timeline
|
Status
|
COV002 (UK), Phase II/III
|
MenACWY or AZD1222
|
FPCD: Q2 2020
LPCD: Q4 2020
|
Initial data readout
Regulatory authorisation (EU, JP, UK)
|
COV003 (Brazil), Phase II/III
|
MenACWY or AZD1222
|
FPCD: Q2 2020
LPCD: Q4 2020
|
Initial data readout
Regulatory authorisation (EU, JP, UK)
|
COV005 ChAdOx1 nCoV-19 ZA[101] (South
Africa), Phase I/II
|
Placebo or AZD1222
|
FPCD: Q2 2020
LPCD: Q4 2020
|
Initial data readout
|
D8110C00001
(US, global), Phase III
|
Placebo or AZD1222
|
FPCD: Q3 2020
LPCD: Q1 2021
|
Primary endpoint met
|
D7220C00001
(Global), Phase II/III
|
AZD1222 or AZD2816
|
FPCD: Q2 2021
First data anticipated:
Q4 2021
|
Recruitment ongoing
|
Trial
|
Design
|
Timeline
|
Status
|
PROVENT
(prophylaxis)
|
Placebo
or AZD7442 300mg i.m.[102]
|
FPCD: Q4 2020
LPCD: Q1 2021
|
Primary endpoint met
|
STORM CHASER
(post-exposure prophylaxis)
|
Placebo
or AZD7442 300mg i.m.
|
FPCD: Q4 2020
LPCD: Q1 2021
|
Primary endpoint not met
|
TACKLE
(outpatient treatment)
|
Placebo
or AZD7442 600mg i.m.
|
FPCD: Q1 2021
LPCD: Q3 2021
|
Primary endpoint met
|
For the nine months ended 30 September
|
2021
|
2020
|
$m
|
$m
|
|
Total Revenue
|
25,406
|
19,207
|
Product Sales
|
25,043
|
18,879
|
Collaboration Revenue
|
363
|
328
|
Cost of Sales
|
(7,812)
|
(3,774)
|
Gross Profit
|
17,594
|
15,433
|
Distribution costs
|
(322)
|
(290)
|
Research and development expense
|
(7,152)
|
(4,272)
|
Selling, general and administrative costs
|
(10,117)
|
(8,084)
|
Other operating income and expense
|
1,345
|
888
|
Operating Profit
|
1,348
|
3,675
|
Finance income
|
42
|
80
|
Finance expense
|
(964)
|
(985)
|
Share of after tax losses in associates and joint
ventures
|
(55)
|
(21)
|
Profit Before Tax
|
371
|
2,749
|
Taxation
|
90
|
(610)
|
Profit for the period
|
461
|
2,139
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
592
|
(191)
|
Net gains on equity investments measured at fair value through
other comprehensive income
|
144
|
974
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
4
|
(1)
|
Tax on items that will not be reclassified to profit or
loss
|
71
|
(70)
|
|
811
|
712
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(368)
|
(121)
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
(275)
|
145
|
Fair value movements on cash flow hedges
|
(103)
|
2
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
137
|
(115)
|
Fair value movements on derivatives designated in net investment
hedges
|
22
|
39
|
Costs of hedging
|
(6)
|
10
|
Tax on items that may be reclassified subsequently to profit or
loss
|
37
|
7
|
|
(556)
|
(33)
|
Other comprehensive income for the period, net of tax
|
255
|
679
|
Total comprehensive income for the period
|
716
|
2,818
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
459
|
2,184
|
Non-controlling interests
|
2
|
(45)
|
|
461
|
2,139
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
714
|
2,864
|
Non-controlling interests
|
2
|
(46)
|
|
716
|
2,818
|
Basic earnings per $0.25 Ordinary Share
|
$0.33
|
$1.66
|
Diluted earnings per $0.25 Ordinary Share
|
$0.33
|
$1.66
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,374
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,382
|
1,313
|
For the quarter ended 30 September
|
2021
|
2020
|
$m
|
$m
|
|
Total Revenue
|
9,866
|
6,578
|
Product Sales
|
9,741
|
6,520
|
Collaboration Revenue
|
125
|
58
|
Cost of Sales
|
(3,757)
|
(1,370)
|
Gross Profit
|
6,109
|
5,208
|
Distribution costs
|
(120)
|
(99)
|
Research and development expense
|
(3,610)
|
(1,495)
|
Selling, general and administrative costs
|
(4,090)
|
(2,730)
|
Other operating income and expense
|
37
|
287
|
Operating (Loss)/Profit
|
(1,674)
|
1,171
|
Finance income
|
15
|
7
|
Finance expense
|
(335)
|
(324)
|
Share of after tax losses in associates and joint
ventures
|
(7)
|
(1)
|
(Loss)/Profit Before Tax
|
(2,001)
|
853
|
Taxation
|
350
|
(202)
|
(Loss)/Profit for the period
|
(1,651)
|
651
|
|
|
|
Other comprehensive (loss)/income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(100)
|
14
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
171
|
(95)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
2
|
(7)
|
Tax on items that will not be reclassified to profit or
loss
|
19
|
9
|
|
92
|
(79)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(427)
|
373
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
(45)
|
162
|
Fair value movements on cash flow hedges
|
(44)
|
133
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
64
|
(114)
|
Fair value movements on derivatives designated in net investment
hedges
|
15
|
(21)
|
Costs of hedging
|
(4)
|
6
|
Tax on items that may be reclassified subsequently to profit or
loss
|
19
|
(22)
|
|
(422)
|
517
|
Other comprehensive (loss)/income for the period, net of
tax
|
(330)
|
438
|
Total comprehensive (loss)/income for the period
|
(1,981)
|
1,089
|
|
|
|
(Loss)/Profit attributable to:
|
|
|
Owners of the Parent
|
(1,652)
|
648
|
Non-controlling interests
|
1
|
3
|
|
(1,651)
|
651
|
Total comprehensive (loss)/income attributable to:
|
|
|
Owners of the Parent
|
(1,982)
|
1,087
|
Non-controlling interests
|
1
|
2
|
|
(1,981)
|
1,089
|
Basic (loss)/earnings per $0.25 Ordinary Share
|
$(1.10)
|
$0.49
|
Diluted (loss)/earnings per $0.25 Ordinary Share
|
$(1.10)
|
$0.49
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,496
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)[103]
|
1,496
|
1,313
|
|
At 30 Sep 2021
|
At 31 Dec2020
|
At 30 Sep 2020
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and equipment
|
9,214
|
8,251
|
7,707
|
Right-of-use assets
|
948
|
666
|
653
|
Goodwill
|
20,081
|
11,845
|
11,711
|
Intangible assets
|
44,104
|
20,947
|
20,613
|
Investments in associates and joint ventures
|
39
|
39
|
42
|
Other investments
|
1,546
|
1,108
|
1,173
|
Derivative financial instruments
|
90
|
171
|
119
|
Other receivables
|
811
|
720
|
685
|
Deferred tax assets
|
3,697
|
3,438
|
3,243
|
|
80,530
|
47,185
|
45,946
|
Current assets
|
|
|
|
Inventories
|
10,528
|
4,024
|
3,683
|
Trade and other receivables
|
8,258
|
7,022
|
5,668
|
Other investments
|
82
|
160
|
374
|
Derivative financial instruments
|
60
|
142
|
37
|
Intangible assets
|
100
|
-
|
-
|
Income tax receivable
|
596
|
364
|
332
|
Cash and cash equivalents
|
7,067
|
7,832
|
8,072
|
|
26,691
|
19,544
|
18,166
|
Total assets
|
107,221
|
66,729
|
64,112
|
|
|
|
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(2,744)
|
(2,194)
|
(3,402)
|
Lease liabilities
|
(229)
|
(192)
|
(183)
|
Trade and other payables
|
(18,663)
|
(15,785)
|
(13,406)
|
Derivative financial instruments
|
(54)
|
(33)
|
(9)
|
Provisions
|
(972)
|
(976)
|
(621)
|
Income tax payable
|
(987)
|
(1,127)
|
(1,321)
|
|
(23,649)
|
(20,307)
|
(18,942)
|
Non-current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(28,206)
|
(17,505)
|
(18,271)
|
Lease liabilities
|
(733)
|
(489)
|
(483)
|
Derivative financial instruments
|
(6)
|
(2)
|
(16)
|
Deferred tax liabilities
|
(6,400)
|
(2,918)
|
(2,576)
|
Retirement benefit obligations
|
(2,449)
|
(3,202)
|
(2,895)
|
Provisions
|
(726)
|
(584)
|
(854)
|
Other payables
|
(5,140)
|
(6,084)
|
(6,457)
|
|
(43,660)
|
(30,784)
|
(31,552)
|
Total liabilities
|
(67,309)
|
(51,091)
|
(50,494)
|
Net assets
|
39,912
|
15,638
|
13,618
|
Equity
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
Share capital
|
387
|
328
|
328
|
Share premium account
|
35,118
|
7,971
|
7,952
|
Other reserves
|
2,039
|
2,024
|
2,039
|
Retained earnings
|
2,200
|
5,299
|
1,876
|
|
39,744
|
15,622
|
12,195
|
Non-controlling interests
|
168
|
16
|
1,423
|
Total equity
|
39,912
|
15,638
|
13,618
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
Profit for the period
|
-
|
-
|
-
|
2,184
|
2,184
|
(45)
|
2,139
|
Other comprehensive income
|
-
|
-
|
-
|
680
|
680
|
(1)
|
679
|
Transfer to other reserves
|
-
|
-
|
(7)
|
7
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,669)
|
(3,669)
|
-
|
(3,669)
|
Issue of Ordinary Shares
|
-
|
11
|
-
|
-
|
11
|
-
|
11
|
Share-based payments charge for the period
|
-
|
-
|
-
|
187
|
187
|
-
|
187
|
Settlement of share plan awards
|
-
|
-
|
-
|
(325)
|
(325)
|
-
|
(325)
|
Net movement
|
-
|
11
|
(7)
|
(936)
|
(932)
|
(46)
|
(978)
|
At 30 Sep 2020
|
328
|
7,952
|
2,039
|
1,876
|
12,195
|
1,423
|
13,618
|
At 1 Jan 2021
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
Profit for the period
|
-
|
-
|
-
|
459
|
459
|
2
|
461
|
Other comprehensive income
|
-
|
-
|
-
|
255
|
255
|
-
|
255
|
Transfer to other reserves
|
-
|
-
|
15
|
(15)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,884)
|
(3,884)
|
-
|
(3,884)
|
Issue of Ordinary Shares
|
59
|
27,147
|
-
|
-
|
27,206
|
-
|
27,206
|
Changes in non-controlling interest
|
-
|
-
|
-
|
-
|
-
|
150
|
150
|
Share-based payments charge for the period
|
-
|
-
|
-
|
384
|
384
|
-
|
384
|
Settlement of share plan awards
|
-
|
-
|
-
|
(811)
|
(811)
|
-
|
(811)
|
Issue of replacement share awards upon acquisition
|
-
|
-
|
-
|
513
|
513
|
-
|
513
|
Net movement
|
59
|
27,147
|
15
|
(3,099)
|
24,122
|
152
|
24,274
|
At 30 Sep 2021
|
387
|
35,118
|
2,039
|
2,200
|
39,744
|
168
|
39,912
|
For the nine months ended 30 September
|
2021
|
2020
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
Profit Before Tax
|
371
|
2,749
|
Finance income and expense
|
922
|
905
|
Share of after tax losses of associates and joint
ventures
|
55
|
21
|
Depreciation, amortisation and impairment
|
4,338
|
2,352
|
Decrease/(increase) in working capital and short-term
provisions
|
2,063
|
(255)
|
Gains on disposal of intangible assets
|
(371)
|
(535)
|
Gains on disposal of investments in associates and joint
ventures
|
(776)
|
-
|
Fair value movements on contingent consideration arising from
business combinations
|
33
|
(14)
|
Non-cash and other movements
|
(370)
|
(484)
|
Cash generated from operations
|
6,265
|
4,739
|
Interest paid
|
(522)
|
(517)
|
Tax paid
|
(1,198)
|
(1,221)
|
Net cash inflow from operating activities
|
4,545
|
3,001
|
Cash flows from investing activities
|
|
|
Acquisition of subsidiaries, net of cash acquired
|
(9,263)
|
-
|
Payments upon vesting of employee share awards attributable to
business combinations
|
(203)
|
-
|
Payment of contingent consideration from business
combinations
|
(470)
|
(663)
|
Purchase of property, plant and equipment
|
(768)
|
(598)
|
Disposal of property, plant and equipment
|
10
|
67
|
Purchase of intangible assets
|
(714)
|
(1,460)
|
Disposal of intangible assets
|
584
|
664
|
Purchase of non-current asset investments
|
(190)
|
(119)
|
Disposal of non-current asset investments
|
-
|
1,121
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
120
|
530
|
Payments to associates and joint ventures
|
(55)
|
(8)
|
Disposal of investments in associates and joint
ventures
|
776
|
-
|
Interest received
|
28
|
43
|
Net cash outflow from investing activities
|
(10,145)
|
(423)
|
Net cash (outflow)/inflow before financing activities
|
(5,600)
|
2,578
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
10
|
11
|
Repayment of loans
|
(2,934)
|
-
|
Issue of loans
|
11,942
|
2,968
|
Dividends paid
|
(3,856)
|
(3,572)
|
Hedge contracts relating to dividend payments
|
(28)
|
(101)
|
Repayment of obligations under leases
|
(173)
|
(157)
|
Movement in short-term borrowings
|
(261)
|
858
|
Net cash inflow from financing activities
|
4,700
|
7
|
Net (decrease)/increase in cash and cash equivalents in the
period
|
(900)
|
2,585
|
Cash and cash equivalents at the beginning of the
period
|
7,546
|
5,223
|
Exchange rate effects
|
(73)
|
(14)
|
Cash and cash equivalents at the end of the period
|
6,573
|
7,794
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
7,067
|
8,072
|
Overdrafts
|
(494)
|
(278)
|
|
6,573
|
7,794
|
|
At 1 Jan 2021
|
Cash flow
|
Acquisitions
|
Non-cash & other
|
Exchange movements
|
At 30 Sep 2021
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(17,505)
|
(11,942)
|
(187)
|
1,257
|
171
|
(28,206)
|
Non-current instalments of leases
|
(489)
|
-
|
(228)
|
(29)
|
13
|
(733)
|
Total long-term debt
|
(17,994)
|
(11,942)
|
(415)
|
1,228
|
184
|
(28,939)
|
Current instalments of loans
|
(1,536)
|
2,934
|
(2,336)
|
(1,260)
|
59
|
(2,139)
|
Current instalments of leases
|
(192)
|
183
|
(34)
|
(193)
|
7
|
(229)
|
Bank collateral
|
(288)
|
183
|
-
|
-
|
-
|
(105)
|
Other short-term borrowings excluding overdrafts
|
(84)
|
78
|
-
|
-
|
-
|
(6)
|
Overdraft
|
(286)
|
(219)
|
-
|
-
|
11
|
(494)
|
Total current debt
|
(2,386)
|
3,159
|
(2,370)
|
(1,453)
|
77
|
(2,973)
|
Gross borrowings
|
(20,380)
|
(8,783)
|
(2,785)
|
(225)
|
261
|
(31,912)
|
Net derivative financial instruments
|
278
|
(16)
|
6
|
(178)
|
-
|
90
|
Net borrowings
|
(20,102)
|
(8,799)
|
(2,779)
|
(403)
|
261
|
(31,822)
|
Cash and cash equivalents
|
7,832
|
(4,767)
|
4,086
|
-
|
(84)
|
7,067
|
Other investments - current
|
160
|
(76)
|
-
|
-
|
(2)
|
82
|
Cash and investments
|
7,992
|
(4,843)
|
4,086
|
-
|
(86)
|
7,149
|
Net Debt
|
(12,110)
|
(13,642)
|
1,307
|
(403)
|
175
|
(24,673)
|
|
|
2021
|
2020
|
||
|
Diabetes alliance
|
Other
|
Total
|
Total
|
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
|
2,932
|
391
|
3,323
|
4,139
|
Additions through business combinations
|
|
-
|
324
|
324
|
-
|
Settlements
|
|
(460)
|
(10)
|
(470)
|
(663)
|
Revaluations
|
|
82
|
(49)
|
33
|
(14)
|
Discount unwind
|
|
148
|
24
|
172
|
212
|
At 30 September
|
|
2,702
|
680
|
3,382
|
3,674
|
|
Fair value
$m
|
Non-current assets
|
|
Property, plant and equipment
|
1,134
|
Right-of-use assets
|
264
|
Intangible assets
|
26,691
|
Other non-current assets
|
301
|
|
28,390
|
Current assets
|
|
Inventories
|
6,886
|
Trade and other receivables
|
2,096
|
Intangible assets
|
100
|
Cash and cash equivalents
|
4,086
|
|
13,168
|
Current liabilities
|
|
Interest-bearing loans and borrowings
|
(2,336)
|
Trade and other payables
|
(1,192)
|
Other current liabilities
|
(40)
|
|
(3,568)
|
Non-current liabilities
|
|
Lease liabilities
|
(228)
|
Deferred tax liabilities
|
(4,191)
|
Other non-current liabilities
|
(697)
|
|
(5,116)
|
|
|
Total net assets acquired
|
32,874
|
|
|
Less: non-controlling interests
|
(150)
|
Goodwill
|
8,334
|
Total fair value of consideration
|
41,058
|
|
|
Less: fair value of equity consideration
|
(27,196)
|
Less: fair value of replacement employee share awards
|
(513)
|
Less: cash and cash equivalents acquired
|
(4,086)
|
Net cash outflow
|
9,263
|
|
Fair value
|
Useful lives
|
|
$m
|
Years
|
Launched medicines - C5 franchise (Soliris/Ultomiris)
|
18,355
|
6-15
|
Launched medicines - Strensiq, Kanuma, Andexxa
|
5,232
|
11-17
|
Medicines in development
|
2,704
|
Not amortised
|
Other intangibles
|
500
|
5-10
|
|
26,791
|
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
|
|
|
|
|||||||||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
9,593
|
21
|
17
|
2,438
|
9
|
4
|
3,871
|
26
|
1,823
|
34
|
24
|
1,461
|
16
|
14
|
Tagrisso
|
3,701
|
17
|
13
|
1,012
|
6
|
1
|
1,294
|
13
|
727
|
45
|
35
|
668
|
16
|
14
|
Imfinzi
|
1,778
|
20
|
17
|
211
|
87
|
77
|
916
|
3
|
347
|
37
|
27
|
304
|
29
|
27
|
Lynparza
|
1,719
|
34
|
31
|
282
|
44
|
40
|
793
|
26
|
456
|
47
|
36
|
188
|
32
|
29
|
Calquence
|
843
|
n/m
|
n/m
|
12
|
n/m
|
n/m
|
752
|
n/m
|
69
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
Koselugo
|
74
|
n/m
|
n/m
|
-
|
-
|
-
|
72
|
n/m
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
Enhertu
|
10
|
n/m
|
n/m
|
8
|
n/m
|
n/m
|
-
|
-
|
2
|
n/m
|
n/m
|
-
|
-
|
-
|
Orpathys
|
10
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
716
|
7
|
1
|
465
|
9
|
3
|
11
|
80
|
112
|
7
|
(1)
|
128
|
(5)
|
(8)
|
Faslodex
|
329
|
(27)
|
(29)
|
122
|
(14)
|
(17)
|
24
|
(47)
|
93
|
(45)
|
(49)
|
90
|
(3)
|
(3)
|
Iressa
|
149
|
(26)
|
(31)
|
122
|
(25)
|
(30)
|
9
|
(13)
|
5
|
(59)
|
(66)
|
13
|
(24)
|
(23)
|
Casodex
|
120
|
(9)
|
(15)
|
92
|
(11)
|
(18)
|
-
|
-
|
2
|
10
|
10
|
26
|
(1)
|
(4)
|
Arimidex
|
106
|
(29)
|
(31)
|
80
|
(34)
|
(37)
|
-
|
-
|
3
|
23
|
31
|
23
|
(11)
|
(11)
|
Others
|
38
|
-
|
(2)
|
22
|
8
|
5
|
-
|
-
|
5
|
32
|
12
|
11
|
(19)
|
(17)
|
BioPharmaceuticals: CVRM
|
6,017
|
15
|
10
|
2,912
|
20
|
15
|
1,548
|
3
|
1,108
|
23
|
15
|
449
|
6
|
1
|
Farxiga
|
2,152
|
57
|
51
|
877
|
80
|
74
|
504
|
31
|
584
|
61
|
50
|
187
|
37
|
31
|
Brilinta
|
1,124
|
(9)
|
(11)
|
256
|
(35)
|
(37)
|
558
|
4
|
263
|
2
|
(5)
|
47
|
7
|
(3)
|
Bydureon
|
293
|
(10)
|
(11)
|
2
|
(24)
|
(17)
|
243
|
(12)
|
43
|
12
|
4
|
5
|
(28)
|
(36)
|
Onglyza
|
284
|
(22)
|
(25)
|
151
|
(2)
|
(6)
|
62
|
(53)
|
47
|
10
|
2
|
24
|
(29)
|
(34)
|
Byetta
|
45
|
(10)
|
(10)
|
11
|
33
|
43
|
20
|
(15)
|
9
|
(16)
|
(21)
|
5
|
(29)
|
(35)
|
Other diabetes
|
43
|
24
|
20
|
12
|
n/m
|
n/m
|
16
|
(20)
|
13
|
47
|
38
|
2
|
24
|
(4)
|
Roxadustat
|
144
|
n/m
|
n/m
|
144
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Lokelma
|
122
|
n/m
|
n/m
|
3
|
(8)
|
(15)
|
82
|
n/m
|
8
|
n/m
|
n/m
|
29
|
n/m
|
n/m
|
Crestor
|
837
|
(5)
|
(9)
|
597
|
7
|
2
|
59
|
(17)
|
43
|
(55)
|
(58)
|
138
|
(12)
|
(14)
|
Seloken/Toprol-XL
|
749
|
21
|
14
|
731
|
23
|
17
|
1
|
(85)
|
9
|
(24)
|
(24)
|
8
|
7
|
(5)
|
Atacand
|
76
|
(58)
|
(58)
|
25
|
(81)
|
(81)
|
3
|
(55)
|
48
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Others
|
148
|
2
|
(3)
|
103
|
10
|
3
|
-
|
-
|
41
|
(9)
|
(11)
|
4
|
(32)
|
(34)
|
BioPharmaceuticals: Respiratory & Immunology
|
4,444
|
16
|
12
|
1,305
|
24
|
17
|
1,757
|
24
|
912
|
5
|
(3)
|
470
|
(5)
|
(9)
|
Symbicort
|
2,047
|
-
|
(3)
|
457
|
8
|
4
|
804
|
6
|
499
|
(4)
|
(11)
|
287
|
(16)
|
(21)
|
Fasenra
|
901
|
35
|
32
|
15
|
55
|
52
|
555
|
31
|
211
|
51
|
40
|
120
|
29
|
24
|
Pulmicort
|
714
|
14
|
7
|
578
|
20
|
13
|
53
|
(1)
|
49
|
(10)
|
(17)
|
34
|
(16)
|
(20)
|
Daliresp
|
168
|
3
|
3
|
2
|
(10)
|
6
|
153
|
9
|
12
|
(35)
|
(40)
|
1
|
28
|
(12)
|
Breztri
|
130
|
n/m
|
n/m
|
40
|
n/m
|
n/m
|
68
|
n/m
|
4
|
n/m
|
n/m
|
18
|
n/m
|
n/m
|
Bevespi
|
39
|
8
|
7
|
3
|
n/m
|
n/m
|
29
|
(14)
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
Saphnelo
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Others
|
444
|
62
|
53
|
210
|
72
|
59
|
94
|
n/m
|
130
|
(2)
|
(9)
|
10
|
(11)
|
(18)
|
Rare disease
|
1,311
|
n/m
|
n/m
|
65
|
n/m
|
n/m
|
785
|
n/m
|
302
|
n/m
|
n/m
|
159
|
n/m
|
n/m
|
Soliris
|
798
|
n/m
|
n/m
|
53
|
n/m
|
n/m
|
460
|
n/m
|
199
|
n/m
|
n/m
|
86
|
n/m
|
n/m
|
Ultomiris
|
297
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
167
|
n/m
|
69
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
Strensiq
|
159
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
124
|
n/m
|
16
|
n/m
|
n/m
|
15
|
n/m
|
n/m
|
Andexxa
|
29
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
20
|
n/m
|
9
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
Kanuma
|
28
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
14
|
n/m
|
9
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Other medicines
|
1,542
|
(17)
|
(19)
|
755
|
4
|
(1)
|
180
|
(40)
|
267
|
(38)
|
(40)
|
340
|
(13)
|
(15)
|
Nexium
|
999
|
(10)
|
(13)
|
576
|
2
|
(1)
|
99
|
(22)
|
47
|
(20)
|
(26)
|
277
|
(24)
|
(26)
|
Synagis
|
170
|
(42)
|
(41)
|
15
|
n/m
|
n/m
|
21
|
(54)
|
81
|
(67)
|
(67)
|
53
|
n/m
|
n/m
|
Losec/Prilosec
|
138
|
(4)
|
(10)
|
116
|
(3)
|
(10)
|
-
|
(96)
|
21
|
29
|
29
|
1
|
(85)
|
(87)
|
FluMist
|
75
|
(35)
|
(37)
|
1
|
n/m
|
n/m
|
23
|
(65)
|
51
|
5
|
1
|
-
|
-
|
-
|
Seroquel XR/IR
|
74
|
(25)
|
(24)
|
36
|
(11)
|
(9)
|
13
|
(42)
|
22
|
-
|
-
|
3
|
(78)
|
(75)
|
Others
|
86
|
(2)
|
(6)
|
11
|
85
|
79
|
24
|
(36)
|
45
|
15
|
9
|
6
|
12
|
3
|
COVID-19
|
2,136
|
n/m
|
n/m
|
1,056
|
n/m
|
n/m
|
-
|
-
|
736
|
n/m
|
n/m
|
344
|
n/m
|
n/m
|
Pandemic COVID-19 vaccine
|
2,136
|
n/m
|
n/m
|
1,056
|
n/m
|
n/m
|
-
|
-
|
736
|
n/m
|
n/m
|
344
|
n/m
|
n/m
|
Total Product Sales
|
25,043
|
33
|
29
|
8,531
|
32
|
27
|
8,141
|
29
|
5,148
|
45
|
35
|
3,223
|
25
|
22
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
3,326
|
18
|
16
|
812
|
5
|
-
|
1,377
|
22
|
640
|
35
|
31
|
497
|
10
|
13
|
Tagrisso
|
1,247
|
8
|
7
|
315
|
(11)
|
(15)
|
441
|
5
|
259
|
46
|
42
|
232
|
14
|
17
|
Imfinzi
|
618
|
16
|
15
|
78
|
58
|
50
|
319
|
2
|
120
|
38
|
35
|
101
|
19
|
21
|
Lynparza
|
588
|
27
|
25
|
96
|
28
|
23
|
270
|
21
|
155
|
36
|
33
|
67
|
32
|
33
|
Calquence
|
354
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
308
|
n/m
|
37
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
Koselugo
|
26
|
n/m
|
n/m
|
-
|
-
|
-
|
25
|
96
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Enhertu
|
5
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
-
|
-
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Orpathys
|
10
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex
|
250
|
9
|
5
|
169
|
22
|
15
|
3
|
n/m
|
38
|
4
|
1
|
40
|
(25)
|
(24)
|
Faslodex
|
103
|
(26)
|
(27)
|
42
|
1
|
(3)
|
8
|
(33)
|
23
|
(59)
|
(59)
|
30
|
(1)
|
2
|
Iressa
|
41
|
(23)
|
(29)
|
34
|
(22)
|
(27)
|
3
|
21
|
2
|
(34)
|
(52)
|
2
|
(54)
|
(44)
|
Casodex
|
38
|
(13)
|
(18)
|
28
|
(19)
|
(25)
|
-
|
(92)
|
1
|
57
|
34
|
9
|
12
|
11
|
Arimidex
|
33
|
(20)
|
(20)
|
24
|
(23)
|
(26)
|
-
|
-
|
1
|
20
|
56
|
8
|
(12)
|
(7)
|
Others
|
13
|
2
|
1
|
7
|
17
|
15
|
-
|
-
|
2
|
65
|
31
|
4
|
(29)
|
(23)
|
BioPharmaceuticals: CVRM
|
2,082
|
16
|
13
|
991
|
21
|
15
|
561
|
9
|
381
|
22
|
20
|
149
|
(1)
|
(1)
|
Farxiga
|
796
|
51
|
48
|
320
|
76
|
69
|
202
|
36
|
213
|
51
|
48
|
61
|
12
|
11
|
Brilinta
|
375
|
(3)
|
(4)
|
76
|
(25)
|
(28)
|
198
|
7
|
85
|
1
|
(1)
|
16
|
10
|
5
|
Bydureon
|
95
|
(13)
|
(13)
|
-
|
(60)
|
(37)
|
81
|
(13)
|
13
|
(3)
|
(2)
|
1
|
(68)
|
(65)
|
Onglyza
|
84
|
(23)
|
(25)
|
42
|
(22)
|
(26)
|
18
|
(37)
|
17
|
17
|
15
|
7
|
(37)
|
(41)
|
Byetta
|
13
|
(11)
|
(6)
|
3
|
(18)
|
(5)
|
6
|
1
|
3
|
9
|
17
|
1
|
(50)
|
(51)
|
Other diabetes
|
14
|
24
|
26
|
5
|
n/m
|
n/m
|
4
|
(32)
|
4
|
37
|
44
|
1
|
22
|
(27)
|
Roxadustat
|
55
|
n/m
|
n/m
|
55
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Lokelma
|
49
|
n/m
|
n/m
|
1
|
(63)
|
(65)
|
32
|
n/m
|
3
|
n/m
|
n/m
|
13
|
n/m
|
n/m
|
Crestor
|
298
|
(1)
|
(4)
|
225
|
18
|
13
|
18
|
(30)
|
11
|
(65)
|
(65)
|
44
|
(18)
|
(17)
|
Seloken/Toprol-XL
|
234
|
4
|
(2)
|
227
|
5
|
-
|
1
|
(81)
|
3
|
(25)
|
(33)
|
3
|
15
|
1
|
Atacand
|
19
|
(65)
|
(65)
|
5
|
(88)
|
(88)
|
1
|
(52)
|
13
|
80
|
80
|
-
|
n/m
|
n/m
|
Others
|
50
|
29
|
23
|
32
|
13
|
6
|
-
|
-
|
16
|
60
|
55
|
2
|
n/m
|
n/m
|
BioPharmaceuticals: Respiratory & Immunology
|
1,483
|
28
|
25
|
420
|
44
|
35
|
609
|
41
|
295
|
5
|
3
|
159
|
2
|
-
|
Symbicort
|
676
|
13
|
11
|
151
|
14
|
9
|
274
|
39
|
155
|
(6)
|
(8)
|
96
|
(8)
|
(11)
|
Fasenra
|
322
|
34
|
33
|
7
|
n/m
|
n/m
|
199
|
32
|
75
|
45
|
42
|
41
|
20
|
19
|
Pulmicort
|
217
|
44
|
36
|
173
|
59
|
48
|
17
|
1
|
15
|
5
|
5
|
12
|
4
|
5
|
Daliresp
|
54
|
(5)
|
(6)
|
-
|
(61)
|
(14)
|
50
|
(3)
|
3
|
(34)
|
(36)
|
1
|
n/m
|
n/m
|
Breztri
|
47
|
n/m
|
n/m
|
14
|
n/m
|
n/m
|
25
|
n/m
|
2
|
n/m
|
n/m
|
6
|
n/m
|
n/m
|
Bevespi
|
13
|
(9)
|
(10)
|
1
|
68
|
34
|
9
|
(28)
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
Saphnelo
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
1
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Others
|
153
|
70
|
64
|
74
|
78
|
66
|
34
|
n/m
|
42
|
(6)
|
(8)
|
3
|
1
|
-
|
Rare disease*
|
1,311
|
5
|
6
|
65
|
(34)
|
(31)
|
785
|
7
|
302
|
12
|
12
|
159
|
7
|
9
|
Soliris*
|
798
|
(3)
|
(2)
|
53
|
(44)
|
(40)
|
460
|
4
|
199
|
(3)
|
(3)
|
86
|
9
|
10
|
Ultomiris*
|
297
|
31
|
31
|
5
|
n/m
|
n/m
|
167
|
25
|
69
|
78
|
77
|
56
|
2
|
5
|
Strensiq*
|
159
|
7
|
8
|
4
|
87
|
84
|
124
|
6
|
16
|
6
|
5
|
15
|
8
|
11
|
Andexxa*
|
29
|
(6)
|
(5)
|
-
|
-
|
-
|
20
|
(30)
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
Kanuma*
|
28
|
26
|
26
|
3
|
n/m
|
n/m
|
14
|
13
|
9
|
16
|
16
|
2
|
85
|
63
|
Other medicines
|
539
|
(27)
|
(27)
|
219
|
(10)
|
(13)
|
80
|
(47)
|
122
|
(36)
|
(37)
|
118
|
(21)
|
(19)
|
Nexium
|
259
|
(35)
|
(36)
|
156
|
(19)
|
(21)
|
32
|
(32)
|
11
|
(50)
|
(51)
|
60
|
(57)
|
(56)
|
Synagis
|
122
|
3
|
5
|
15
|
n/m
|
n/m
|
16
|
(36)
|
38
|
(61)
|
(62)
|
53
|
n/m
|
n/m
|
Losec/Prilosec
|
38
|
(16)
|
(21)
|
32
|
(16)
|
(23)
|
-
|
-
|
6
|
(9)
|
(9)
|
-
|
-
|
-
|
FluMist
|
72
|
(37)
|
(39)
|
-
|
-
|
-
|
23
|
(65)
|
49
|
1
|
(2)
|
-
|
n/m
|
n/m
|
Seroquel XR/IR
|
24
|
(32)
|
(30)
|
12
|
(13)
|
(10)
|
3
|
(66)
|
7
|
9
|
8
|
2
|
(69)
|
(64)
|
Others
|
24
|
23
|
20
|
4
|
50
|
39
|
6
|
33
|
11
|
3
|
4
|
3
|
72
|
41
|
COVID-19
|
1,000
|
n/m
|
n/m
|
601
|
n/m
|
n/m
|
-
|
-
|
165
|
n/m
|
n/m
|
234
|
n/m
|
n/m
|
Pandemic COVID-19 vaccine
|
1,000
|
n/m
|
n/m
|
601
|
n/m
|
n/m
|
-
|
-
|
165
|
n/m
|
n/m
|
234
|
n/m
|
n/m
|
Total Product Sales
|
9,741
|
49
|
47
|
3,108
|
46
|
40
|
3,412
|
53
|
1,905
|
51
|
48
|
1,316
|
45
|
47
|
|
|
|
Q1 2021
|
|
|
Q2 2021
|
|
|
Q3 2021
|
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
2,981
|
3
|
1
|
3,286
|
10
|
11
|
3,326
|
1
|
2
|
Tagrisso
|
1,149
|
(1)
|
(3)
|
1,306
|
14
|
14
|
1,247
|
(5)
|
(4)
|
Imfinzi
|
556
|
-
|
(1)
|
604
|
9
|
10
|
618
|
2
|
3
|
Lynparza
|
543
|
9
|
8
|
588
|
8
|
9
|
588
|
-
|
1
|
Calquence
|
209
|
15
|
15
|
280
|
34
|
34
|
354
|
26
|
26
|
Koselugo
|
21
|
23
|
23
|
26
|
23
|
22
|
26
|
-
|
2
|
Enhertu
|
1
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
5
|
64
|
63
|
Orpathys
|
-
|
-
|
-
|
-
|
-
|
-
|
10
|
n/m
|
n/m
|
Zoladex
|
221
|
2
|
-
|
244
|
10
|
11
|
250
|
2
|
3
|
Faslodex
|
122
|
(6)
|
(8)
|
105
|
(14)
|
(12)
|
103
|
(2)
|
(2)
|
Iressa
|
61
|
(9)
|
(11)
|
47
|
(23)
|
(22)
|
41
|
(11)
|
(14)
|
Casodex
|
42
|
7
|
5
|
41
|
(2)
|
(1)
|
38
|
(7)
|
(8)
|
Arimidex
|
44
|
22
|
18
|
29
|
(34)
|
(33)
|
33
|
16
|
19
|
Others
|
12
|
(4)
|
(6)
|
13
|
13
|
11
|
13
|
(5)
|
(4)
|
BioPharmaceuticals: CVRM
|
1,912
|
4
|
1
|
2,023
|
6
|
6
|
2,082
|
3
|
3
|
Farxiga
|
624
|
6
|
4
|
732
|
17
|
18
|
796
|
9
|
9
|
Brilinta
|
374
|
3
|
1
|
375
|
-
|
1
|
375
|
-
|
1
|
Bydureon
|
103
|
(16)
|
(17)
|
95
|
(8)
|
(7)
|
95
|
1
|
2
|
Onglyza
|
101
|
(3)
|
(6)
|
99
|
(2)
|
(2)
|
84
|
(15)
|
(15)
|
Byetta
|
16
|
(14)
|
(15)
|
16
|
(4)
|
(7)
|
13
|
(15)
|
(7)
|
Other diabetes
|
13
|
7
|
1
|
15
|
14
|
14
|
14
|
(9)
|
(4)
|
Roxadustat
|
39
|
n/m
|
n/m
|
51
|
32
|
32
|
55
|
7
|
7
|
Lokelma
|
33
|
16
|
18
|
39
|
21
|
21
|
49
|
25
|
26
|
Crestor
|
274
|
(8)
|
(9)
|
265
|
(3)
|
(3)
|
298
|
12
|
13
|
Seloken/Toprol-XL
|
250
|
25
|
21
|
266
|
6
|
7
|
234
|
(12)
|
(13)
|
Atacand
|
34
|
(45)
|
(45)
|
23
|
(35)
|
(32)
|
19
|
(15)
|
(18)
|
Others
|
51
|
12
|
10
|
47
|
(7)
|
(10)
|
50
|
6
|
7
|
BioPharmaceuticals: Respiratory & Immunology
|
1,541
|
1
|
(1)
|
1,420
|
(8)
|
(7)
|
1,483
|
4
|
5
|
Symbicort
|
691
|
2
|
-
|
680
|
(2)
|
(1)
|
676
|
(1)
|
-
|
Fasenra
|
260
|
(8)
|
(9)
|
320
|
23
|
23
|
322
|
1
|
1
|
Pulmicort
|
330
|
(10)
|
(13)
|
167
|
(50)
|
(49)
|
217
|
30
|
30
|
Daliresp
|
60
|
11
|
10
|
54
|
(10)
|
(9)
|
54
|
-
|
(2)
|
Breztri
|
27
|
n/m
|
n/m
|
56
|
n/m
|
n/m
|
47
|
(15)
|
(15)
|
Bevespi
|
13
|
7
|
8
|
13
|
1
|
3
|
13
|
(1)
|
(2)
|
Saphnelo
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
n/m
|
n/m
|
Others
|
160
|
28
|
25
|
130
|
(19)
|
(19)
|
153
|
17
|
19
|
Rare disease†
|
-
|
-
|
-
|
-
|
-
|
-
|
1,311
|
(2)
|
(1)
|
Soliris†
|
-
|
-
|
-
|
-
|
-
|
-
|
798
|
(6)
|
(4)
|
Ultomiris†
|
-
|
-
|
-
|
-
|
-
|
-
|
297
|
7
|
8
|
Strensiq†
|
-
|
-
|
-
|
-
|
-
|
-
|
159
|
(2)
|
(2)
|
Andexxa†
|
-
|
-
|
-
|
-
|
-
|
-
|
29
|
5
|
6
|
Kanuma†
|
-
|
-
|
-
|
-
|
-
|
-
|
28
|
9
|
9
|
Other medicines
|
548
|
(25)
|
(26)
|
454
|
(17)
|
(16)
|
539
|
19
|
20
|
Nexium
|
403
|
7
|
5
|
336
|
(17)
|
(15)
|
259
|
(23)
|
(23)
|
Synagis
|
24
|
(69)
|
(69)
|
24
|
1
|
1
|
122
|
n/m
|
n/m
|
Losec/Prilosec
|
54
|
39
|
36
|
46
|
(14)
|
(15)
|
38
|
(18)
|
(17)
|
FluMist
|
2
|
(99)
|
(99)
|
1
|
(51)
|
(71)
|
72
|
n/m
|
n/m
|
Seroquel XR/IR
|
29
|
51
|
38
|
21
|
(29)
|
(22)
|
24
|
17
|
14
|
Others
|
36
|
(6)
|
(4)
|
26
|
(28)
|
(32)
|
24
|
(8)
|
(5)
|
COVID-19
|
275
|
n/m
|
n/m
|
862
|
n/m
|
n/m
|
1,000
|
16
|
18
|
Pandemic COVID-19 vaccine
|
275
|
n/m
|
n/m
|
862
|
n/m
|
n/m
|
1,000
|
16
|
18
|
Total Product Sales
|
7,257
|
4
|
1
|
8,045
|
11
|
12
|
9,741
|
21
|
22
|
|
Q1 2020
|
Q2 2020
|
Q3 2020
|
Q4 2020
|
||||||||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
Actual
|
CER
|
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
$m
|
% change
|
% change
|
Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
2,831
|
8
|
6
|
2,908
|
3
|
2
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
1,155
|
12
|
9
|
1,157
|
-
|
(1)
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
533
|
8
|
6
|
555
|
4
|
3
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
464
|
11
|
8
|
496
|
7
|
6
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
145
|
36
|
35
|
182
|
25
|
25
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
13
|
75
|
75
|
17
|
34
|
34
|
Zoladex
|
225
|
15
|
15
|
217
|
(3)
|
-
|
230
|
6
|
3
|
216
|
(6)
|
(7)
|
Faslodex
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
138
|
(5)
|
(8)
|
130
|
(6)
|
(7)
|
Iressa
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
54
|
(23)
|
(24)
|
67
|
24
|
19
|
Arimidex
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
42
|
(28)
|
(27)
|
36
|
(14)
|
(16)
|
Casodex
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
44
|
(7)
|
(8)
|
39
|
(11)
|
(14)
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
13
|
4
|
3
|
13
|
2
|
2
|
BioPharmaceuticals: CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
1,794
|
2
|
-
|
1,842
|
3
|
1
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
525
|
19
|
16
|
586
|
11
|
10
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
385
|
(12)
|
(13)
|
363
|
(6)
|
(6)
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
110
|
(6)
|
(6)
|
105
|
(4)
|
(5)
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
109
|
(5)
|
(7)
|
122
|
12
|
11
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
15
|
1
|
4
|
19
|
26
|
24
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
11
|
9
|
6
|
12
|
11
|
15
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
21
|
22
|
26
|
28
|
37
|
28
|
Crestor
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
300
|
7
|
5
|
298
|
(1)
|
(4)
|
Seloken/Toprol-XL
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
225
|
4
|
3
|
200
|
(11)
|
(13)
|
Atacand
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
54
|
(9)
|
(12)
|
63
|
16
|
14
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
39
|
(19)
|
(22)
|
46
|
18
|
17
|
BioPharmaceuticals: Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
1,161
|
4
|
1
|
1,528
|
32
|
29
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
599
|
(8)
|
(11)
|
680
|
13
|
13
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
151
|
56
|
49
|
368
|
n/m
|
n/m
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
240
|
5
|
4
|
283
|
18
|
17
|
Daliresp
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
57
|
8
|
11
|
54
|
(4)
|
(6)
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
14
|
47
|
46
|
12
|
(16)
|
(17)
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
10
|
45
|
48
|
6
|
(39)
|
(38)
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
90
|
27
|
22
|
125
|
39
|
35
|
Other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
734
|
30
|
27
|
733
|
-
|
(2)
|
Nexium
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
401
|
6
|
4
|
377
|
(6)
|
(7)
|
Synagis
|
85
|
35
|
35
|
90
|
6
|
7
|
118
|
31
|
29
|
78
|
(34)
|
(33)
|
FluMist
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
116
|
n/m
|
n/m
|
179
|
55
|
50
|
Losec/Prilosec
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
45
|
-
|
-
|
39
|
(15)
|
(18)
|
Seroquel XR/IR
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
35
|
32
|
29
|
19
|
(45)
|
(42)
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
19
|
(17)
|
(19)
|
41
|
n/m
|
n/m
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
6,520
|
8
|
6
|
7,011
|
8
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YTD 2021
|
YTD 2020
|
FY 2020
|
FY 2019
|
||||
|
$m
|
$m
|
$m
|
$m
|
|||||
Initial Collaboration Revenue
|
|
|
|
|
|
||||
Nexium (Japan)
|
|
75
|
-
|
-
|
-
|
||||
Ongoing Collaboration Revenue
|
|
|
|
|
|
||||
Lynparza: regulatory
milestones
|
|
-
|
135
|
160
|
60
|
||||
Lynparza: sales
milestones
|
|
-
|
-
|
300
|
450
|
||||
Lynparza/Koselugo: option payments
|
|
-
|
-
|
-
|
100
|
||||
Crestor (Spain)
|
|
-
|
-
|
-
|
39
|
||||
Enhertu: share of gross
profits
|
|
134
|
63
|
94
|
-
|
||||
roxadustat: share of gross profits
|
|
4
|
19
|
30
|
-
|
||||
Royalty income
|
|
137
|
47
|
62
|
62
|
||||
Other Ongoing Collaboration Revenue
|
|
13
|
64
|
81
|
108
|
||||
Total
|
|
363
|
328
|
727
|
819
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
YTD 2021
|
YTD 2020
|
FY 2020
|
FY 2019
|
|
$m
|
$m
|
$m
|
$m
|
|
Divestment of Viela Bio, Inc. shareholding
|
|
776
|
-
|
-
|
-
|
Crestor (Europe ex-UK and
Spain)
|
|
309
|
-
|
-
|
-
|
Oxra and Oxramet (India)
|
|
40
|
-
|
-
|
-
|
Hypertension medicines (ex-US, India and Japan)
|
|
-
|
350
|
350
|
-
|
Monetisation of an asset previously licensed
|
|
-
|
120
|
120
|
-
|
brazikumab licence termination funding
|
|
77
|
51
|
107
|
-
|
Inderal, Tenormin, Seloken and Omepral (Japan)
|
|
-
|
51
|
51
|
-
|
Synagis (US)
|
|
-
|
-
|
-
|
515
|
Losec (ex-China, Japan, US
and Mexico)
|
|
-
|
-
|
-
|
243
|
Seroquel and Seroquel XR (US, Canada, Europe and
Russia)
|
|
-
|
-
|
-
|
213
|
Arimidex and Casodex (various countries)
|
|
-
|
-
|
-
|
181
|
Nexium (Europe)
and Vimovo (ex-US)
|
|
-
|
-
|
54
|
-
|
Atacand
|
|
-
|
-
|
400
|
-
|
Other
|
|
143
|
316
|
446
|
389
|
Total
|
|
1,345
|
888
|
1,528
|
1,541
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|